vs
STANDARD BIOTOOLS INC.（LAB）与凯特制药（NAMS）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是凯特制药的1.0倍（$19.6M vs $19.1M），凯特制药净利率更高（-90.7% vs -177.4%，领先86.7%），凯特制药同比增速更快（740.1% vs -11.5%），STANDARD BIOTOOLS INC.自由现金流更多（$-23.1M vs $-37.8M）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
凯特制药是一家美国生物技术企业，专注于研发癌症免疫治疗产品，核心方向为基因工程改造的自体嵌合抗原受体T细胞（CAR-T）疗法，这是一种基于嵌合抗原受体与T细胞的细胞治疗技术。公司成立于2009年，总部位于加利福尼亚州圣莫尼卡，2017年被吉利德科学收购。
LAB vs NAMS — 直观对比
营收规模更大
LAB
是对方的1.0倍
$19.1M
营收增速更快
NAMS
高出751.5%
-11.5%
净利率更高
NAMS
高出86.7%
-177.4%
自由现金流更多
LAB
多$14.7M
$-37.8M
损益表 — Q3 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $19.1M |
| 净利润 | $-34.7M | $-17.4M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | -186.1% |
| 净利率 | -177.4% | -90.7% |
| 营收同比 | -11.5% | 740.1% |
| 净利润同比 | -28.8% | 55.5% |
| 每股收益（稀释后） | $-0.09 | $-0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABNAMS
| Q3 25 | $19.6M | — | ||
| Q2 25 | $21.8M | $19.1M | ||
| Q1 25 | $40.8M | — | ||
| Q4 24 | — | $12.8M | ||
| Q3 24 | $22.1M | $29.1M | ||
| Q2 24 | $22.5M | — | ||
| Q1 24 | $45.5M | — | ||
| Q4 23 | $28.2M | — |
净利润LABNAMS
| Q3 25 | $-34.7M | — | ||
| Q2 25 | $-33.5M | $-17.4M | ||
| Q1 25 | $-26.0M | — | ||
| Q4 24 | — | $-92.2M | ||
| Q3 24 | $-26.9M | $-16.6M | ||
| Q2 24 | $-45.7M | — | ||
| Q1 24 | $-32.2M | — | ||
| Q4 23 | $-19.8M | — |
毛利率LABNAMS
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — | ||
| Q4 23 | 47.6% | — |
营业利润率LABNAMS
| Q3 25 | -168.5% | — | ||
| Q2 25 | -118.1% | -186.1% | ||
| Q1 25 | -80.8% | — | ||
| Q4 24 | — | -338.5% | ||
| Q3 24 | -120.9% | -85.9% | ||
| Q2 24 | -134.5% | — | ||
| Q1 24 | -132.2% | — | ||
| Q4 23 | -75.9% | — |
净利率LABNAMS
| Q3 25 | -177.4% | — | ||
| Q2 25 | -153.7% | -90.7% | ||
| Q1 25 | -63.8% | — | ||
| Q4 24 | — | -721.7% | ||
| Q3 24 | -122.0% | -57.2% | ||
| Q2 24 | -203.3% | — | ||
| Q1 24 | -70.6% | — | ||
| Q4 23 | -70.2% | — |
每股收益（稀释后）LABNAMS
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.09 | $-0.15 | ||
| Q1 25 | $-0.07 | — | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | $-0.07 | $-0.18 | ||
| Q2 24 | $-0.12 | — | ||
| Q1 24 | $-0.27 | — | ||
| Q4 23 | $-0.24 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $739.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $778.5M |
| 总资产 | $539.6M | $815.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABNAMS
| Q3 25 | $129.4M | — | ||
| Q2 25 | $158.6M | $739.2M | ||
| Q1 25 | $150.9M | — | ||
| Q4 24 | — | $834.2M | ||
| Q3 24 | $210.6M | $422.7M | ||
| Q2 24 | $269.8M | — | ||
| Q1 24 | $287.1M | — | ||
| Q4 23 | $51.7M | — |
总债务LABNAMS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — | ||
| Q4 23 | $63.5M | — |
股东权益LABNAMS
| Q3 25 | $399.7M | — | ||
| Q2 25 | $424.5M | $778.5M | ||
| Q1 25 | $454.6M | — | ||
| Q4 24 | — | $757.5M | ||
| Q3 24 | $489.3M | $378.9M | ||
| Q2 24 | $510.3M | — | ||
| Q1 24 | $577.3M | — | ||
| Q4 23 | $-148.1M | — |
总资产LABNAMS
| Q3 25 | $539.6M | — | ||
| Q2 25 | $557.0M | $815.1M | ||
| Q1 25 | $579.6M | — | ||
| Q4 24 | — | $864.6M | ||
| Q3 24 | $681.5M | $439.2M | ||
| Q2 24 | $708.7M | — | ||
| Q1 24 | $777.7M | — | ||
| Q4 23 | $323.1M | — |
负债/权益比LABNAMS
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-37.7M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-37.8M |
| 自由现金流率自由现金流/营收 | -118.1% | -197.2% |
| 资本支出强度资本支出/营收 | 4.5% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-119.7M |
8季度趋势，按日历期对齐
经营现金流LABNAMS
| Q3 25 | $-22.2M | — | ||
| Q2 25 | $-20.7M | $-37.7M | ||
| Q1 25 | $-30.3M | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | $-27.9M | $-12.5M | ||
| Q2 24 | $-39.0M | — | ||
| Q1 24 | $-62.5M | — | ||
| Q4 23 | $-14.1M | — |
自由现金流LABNAMS
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | $-37.8M | ||
| Q1 25 | $-35.3M | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | $-30.1M | $-12.6M | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — | ||
| Q4 23 | $-14.1M | — |
自由现金流率LABNAMS
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | -197.2% | ||
| Q1 25 | -86.6% | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | -136.4% | -43.2% | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — | ||
| Q4 23 | -50.2% | — |
资本支出强度LABNAMS
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | 0.5% | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 10.2% | 0.3% | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — | ||
| Q4 23 | 0.3% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
NAMS
暂无分部数据
